Scientists Say NAD+ Evidence Lags Behind Wellness Claims
Scientists studying NAD+ say the evidence for longevity claims is still early, even as supplements, injectables and IV infusions draw attention from celebrities and biohackers. Christopher Martens said, “I think now the cart may be well ahead of the horse.”
The strongest human data have not yet established the health benefits of boosting NAD+, and most trials have tested NR and NMN rather than NAD+ itself. Dr. Shalender Bhasin said, “But we are still in the early stages of human studies and the health benefits of augmenting NAD+ are yet to be established in large human studies.”
Martens on early enthusiasm
Martens, director of the Delaware Center for Cognitive Aging Research, said, “Initially it was exciting” when interest in the field began to build. He added that publicity around NAD+ now appears to be moving faster than the evidence supporting the claims made for it.
That gap matters to people being sold products that marketers say can boost energy, combat aging and enhance recovery. Wellness clinics describe NAD+ therapies as a fountain of youth that works on a cellular level, but the data now in hand do not match that language.
Bhasin on human studies
Bhasin, director of the Boston Pepper Aging Research Center at Brigham and Women's Hospital, said, “As a hypothesis, as an idea, it's very attractive.” He said the health benefits of augmenting NAD+ still have not been established in large human studies.
NAD+ itself is involved in mitochondrial energy production and DNA repair, and levels decline as people get older. That basic biology has helped fuel interest, but the human research has remained limited.
Animal results versus human trials
Animal studies on NAD+ have shown improvements in mitochondrial health, strength, exercise performance, metabolic abnormalities and inflammation. Dr. Samuel Klein, director of the Center for Human Nutrition at Washington University School of Medicine in St. Louis, said, “In rodents and mice — not in humans — NAD+ is miraculous.”
Human trials have mostly looked at the precursors NR and NMN in small studies. Some trials have reported promising data in women with prediabetes, newly diagnosed patients with Parkinson's disease and people with peripheral artery disease, while other metabolic health studies have not matched the animal findings.
Early 1900s lessons
The history around NAD+ reaches back to the early 1900s, when pellagra was an epidemic tied to a diet deficient in vitamin B3 and dangerously low NAD+ levels. That past explains why researchers continue to study the molecule, even as the current human evidence remains far short of the claims being marketed now.
For readers deciding whether to spend hundreds or thousands of dollars on NAD+ products, the practical answer from the available human studies is narrow: the science has not yet shown the broad longevity or energy benefits being advertised, and the most encouraging findings so far come from small trials rather than large human studies.
